Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Mirviss Jeffrey B.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,506Price:$66.45
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
Filings by filing date
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Mirviss Jeffrey B.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,506Price:$66.45
-
Feb 14, 2024 (filed on Mar 11, 2024)Insider Name:Thepaut Eric Francis YvesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:--Price:$65.95
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,421Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,351Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Woodworth EmilyOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 300 Boston Scientific Way MARLBOROUGH MA 01752-1291 |
Tel: | N/A |
Website: | https://www.bostonscientific.com/en-US/Home.html |
IR: | See website |
Key People | ||
Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer | Emily Woodworth Senior Vice President, Chief Accounting Officer, Controller | Daniel J. Brennan Chief Financial Officer, Executive Vice President |
Wendy Carruthers Executive Vice President - Human Resources | Arthur Crosswell Butcher Executive Vice President, Group President, MedSurg and Asia Pacific | Joseph M. Fitzgerald Executive Vice President, Group President - Cardiology |
Ian T. Meredith Executive Vice President, Global Chief Medical Officer | Jeffrey B. Mirviss Executive Vice President and President - Peripheral Interventions | John Bradley Sorenson Executive Vice President - Global Operations | Eric Francis Yves Thepaut Executive Vice President and President - Europe, Middle East and Africa |
Business Overview |
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Boston Scientific Corporation revenues increased 12% to $14.24B. Net income applicable to common stockholders increased from $642M to $1.57B. Revenues reflect Cardiovascular segment increase of 13% to $8.82B, MedSurg segment increase of 10% to $5.42B, United States segment increase of 10% to $8.43B, EMEA (Europe, Middle East and Africa) segment increase of 13% to $2.86B. |
Employees: | 48,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $109,101M as of Dec 31, 2023 |
Annual revenue (TTM): | $14,240M as of Dec 31, 2023 |
EBITDA (TTM): | $4,079M as of Dec 31, 2023 |
Net annual income (TTM): | $1,571M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,764M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $8,237M as of Dec 31, 2023 |
Shares outstanding: | 1,469,895,391 as of Mar 8, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |